Phase 2a study initiated to examine synthetic DMT for treatment-resistant depression

A biotech company based in the U.K. announced that it has initiated a phase 2a study for BPL-003 for treatment-resistant depression.
According to a release issued by Beckley Psytech, the study will occur at King’s College Hospital and Hammersmith Medicines Research in the U.K. and seeks to explore the effects of a single dose of BPL-003, a proprietary intranasal formulation of synthetic 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), in combination with psychological support, for those with moderate to severe TRD symptoms who are not taking concomitant antidepressants.
“Conditions

A biotech company based in the U.K. announced that it has initiated a phase 2a study for BPL-003 for treatment-resistant depression.
According to a release issued by Beckley Psytech, the study will occur at King’s College Hospital and Hammersmith Medicines Research in the U.K. and seeks to explore the effects of a single dose of BPL-003, a proprietary intranasal formulation of synthetic 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), in combination with psychological support, for those with moderate to severe TRD symptoms who are not taking concomitant antidepressants.
“Conditions